Successful treatment of IBL-like T-cell lymphoma with cyclosporin A: two case reports with special reference to serum cytokine levels.
The prognosis of immunoblastic lymphadenopathy (IBL)-like T-cell lymphoma is grave, and its effective treatments have not been established. We applied oral cyclosporin A (CsA) treatment to two cases of IBL-like T-cell lymphoma, and succeeded in achieving complete remissions. CsA is known to have a suppressive effect on the immune system, most notably T-cells, but it also has a direct cytotoxic/apoptosis-inducing effect on lymphocytes. Its combined effects on neoplastic T-cells might have played an important role in achieving remission. In both cases, serum levels of interleukin-12 (IL-12) and tumor necrosis factor-alpha (TNF-alpha) were elevated and decreased or returned to normal after achieving remissions. Considering that both cytokines represent monokines, it seems that a macrophage system is also involved in the pathogenesis of this disorder. Our two cases indicate that administration of CsA may be an effective therapy for IBL-like T-cell lymphoma.
Takemori
N
N
Department of Internal Medicine, JA Asahikawa Kosei Hospital.
Kodaira
J
J
Sato
T
T
Sakurai
H
H
Akakura
N
N
Kimura
S
S
Katagiri
M
M
D000284:Administration, Oral; D000368:Aged; D016572:Cyclosporine / Q000008:administration & dosage*; D016207:Cytokines / Q000097:blood*; D005260:Female; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000188:drug therapy* / Q000276:immunology; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D016896:Treatment Outcome
D016207:Cytokines; D007166:Immunosuppressive Agents; D016572:Cyclosporine